CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended			9 Months Ended			82 Months Ended
	Sep. 30, 2012	Sep. 30, 2011		Sep. 30, 2012	Sep. 30, 2011		Sep. 30, 2012
Costs and Expenses:
Research and development	$ 8,245,620	$ 3,882,803		$ 21,210,028	$ 7,715,379		$ 49,623,182
Purchased in-process research and development							28,156,502
General and administrative	1,843,150	1,102,844		5,492,766	4,524,875		25,137,408
Loss from Operations	(10,088,770)	(4,985,647)		(26,702,794)	(12,240,254)		(102,917,092)
Interest and investment income	63,161	20,000		149,955	64,070		428,141
Interest expense					(11,877)		(11,877)
Other income				255,539			1,112,516
Change in fair value of derivative instruments-warrants	140,322	4,382,796		(1,169,079)	3,346,421		4,384,736
Total Other Income/(Expense)	203,483	4,402,796		(763,585)	3,398,614		5,913,516
Loss from Continuing Operations	(9,885,287)	(582,851)		(27,466,379)	(8,841,640)		(97,003,576)
Loss from discontinued operations							(71,821)
Net Loss	$ (9,885,287)	$ (582,851)		$ (27,466,379)	$ (8,841,640)		$ (97,075,397)
Weighted Average Common Shares Outstanding Basic and Diluted (in shares)	65,806,178	47,308,946	[1]	60,194,004	46,708,403	[1]
Net Loss per Common Share, Basic and Diluted (in dollars per share)	$ (0.15)	$ (0.01)	[1]	$ (0.46)	$ (0.19)	[1]

[1] Restated for 1:2 reverse stock split effective November 30, 2011.